1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsOculomics Initiative is sponsored by National Institutes of Health (NIH). Aims to develop and apply novel, noninvasive ocular imaging technologies and machine learning algorithms to identify biomarkers for diseases affecting the entire body, including retinal diseases.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Oculomics | NIH Common Fund What is the Venture Program? Watch the Video What is the NIH Common Fund Venture Program? This video provides an overview of the Common Fund Venture Program and how Venture Program initiatives are special.
The Common Fund Development and Application of Imaging Technologies for Oculomics (Oculomics) Venture Initiative aims to support development and application of novel, noninvasive ocular (eye) imaging technologies, machine learning algorithms, and other tools to identify highly sensitive and specific biomarkers for diseases that affect the entire body.
Oculomics can have a significant impact on early detection of diseases before the onset of symptoms, and can help clinicians with early disease intervention, risk assessment, tracking disease progression, and supportive therapeutics. Ocular imaging technologies provide a unique opportunity for measurements of diabetes, hypertension, stroke, and coronary, inflammatory, metabolic, and renal diseases.
Because of its noninvasive nature, Oculomics has the potential to provide advanced health care to all communities, including rural and underserved communities throughout the world. To learn more about the Venture Program Oculomics Initiative, watch this informative video: The Venture Program Oculomics Initiative has announced its first awards! Check out the new awards that will help advance the field of Oculomics.
On January 25th, the NIH Council of Councils approved the concept of the NIH Common Fund's Venture Program. Find out more by browsing the presentation slides and program description . Or watch the videocast .
Have a question? Reach out to us at [email protected] This page last reviewed on
According to the current listing, eligibility includes: Universities, Nonprofits, State/local governments, For-profit organizations. Confirm the full requirements in the official notice before applying.
Oculomics Initiative is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
Past winners and funding trends for this program
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article